论文部分内容阅读
我们从1991年11月至1995年4月研究了 Octreotide(善得定)治疗肝硬化门脉高压症并发食管静脉曲张破裂出血(EVB)的临床疗效,安全性及其对实验性肝硬化门脉高压症血液动力学的影响,并对其可能作用机理进行了探讨.1.研究对象:(1)1991年11～1995年4月,因上消化道出血急诊患者,未经特殊治疗或经治疗4～6小时无效者;(2)通过胃管抽出鲜红色血液,证实有活动性出血者;(3)出血停止后24～48小时胃镜检查确诊为 EVB,而无其他任何可能引起出血病灶者。本研究共50例(北京佑安医院36例,北京友谊医院14例);根椐用 Octreotide 前是否经特殊治疗分为早期治疗组(16例,男/女7:1,平均年龄49岁)和晚期治疗组(34例,男/女7.5:1,平均年龄51.2岁)。
We studied the clinical efficacy, safety and safety of Octreotide in the treatment of cirrhosis and portal hypertension with esophageal variceal bleeding (EVB) from November 1991 to April 1995. Hypertension and hemodynamics, and its possible mechanism of action were discussed.MATERIALS: (1) From November 1991 to April 1995, the patients with upper gastrointestinal bleeding emergency, without special treatment or after treatment 4 to 6 hours invalid; (2) through the tube out of bright red blood, confirmed active bleeding; (3) 24 to 48 hours after the cessation of bleeding gastroscopy diagnosed as EVB, without any other possible cause bleeding disorders . Fifty patients (Beijing You’an Hospital, Beijing Friendship Hospital, Beijing: 14 cases) were divided into two groups: early treatment group (16 cases, male / female 7: 1, mean age 49 years) And late treatment group (34 patients, male / female 7.5: 1, mean age 51.2 years).